RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 133 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,180,000 | -10.5% | 344,900 | -8.5% | 0.00% | 0.0% |
| Q4 2020 | $1,319,000 | +43.1% | 376,758 | -1.9% | 0.00% | 0.0% |
| Q3 2020 | $922,000 | +34.2% | 384,058 | +2.2% | 0.00% | 0.0% |
| Q2 2020 | $687,000 | +17.4% | 375,658 | +0.2% | 0.00% | 0.0% |
| Q1 2020 | $585,000 | -43.0% | 374,858 | -21.8% | 0.00% | 0.0% |
| Q4 2019 | $1,026,000 | +4.6% | 479,658 | -8.5% | 0.00% | 0.0% |
| Q3 2019 | $981,000 | -19.3% | 524,458 | +12.6% | 0.00% | 0.0% |
| Q2 2019 | $1,215,000 | -1.5% | 465,600 | -3.0% | 0.00% | -50.0% |
| Q1 2019 | $1,234,000 | +11.8% | 480,000 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $1,104,000 | -32.3% | 480,000 | -5.5% | 0.00% | 0.0% |
| Q3 2018 | $1,631,000 | +4.7% | 508,094 | -7.7% | 0.00% | 0.0% |
| Q2 2018 | $1,558,000 | -50.1% | 550,694 | -37.5% | 0.00% | -50.0% |
| Q1 2018 | $3,121,000 | -8.7% | 881,500 | 0.0% | 0.00% | -20.0% |
| Q4 2017 | $3,420,000 | +52.7% | 881,500 | 0.0% | 0.01% | +66.7% |
| Q3 2017 | $2,239,000 | -6.9% | 881,500 | 0.0% | 0.00% | -25.0% |
| Q2 2017 | $2,406,000 | -17.5% | 881,500 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $2,918,000 | +39.1% | 881,500 | 0.0% | 0.01% | +25.0% |
| Q4 2016 | $2,098,000 | -35.1% | 881,500 | 0.0% | 0.00% | -20.0% |
| Q3 2016 | $3,235,000 | +64.5% | 881,500 | 0.0% | 0.01% | +66.7% |
| Q2 2016 | $1,966,000 | +7.2% | 881,500 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,834,000 | -31.3% | 881,500 | 0.0% | 0.00% | -25.0% |
| Q4 2015 | $2,671,000 | +22.7% | 881,500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $2,177,000 | -23.1% | 881,500 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $2,830,000 | +108.4% | 881,500 | +39.5% | 0.00% | +100.0% |
| Q1 2015 | $1,358,000 | 0.0% | 631,700 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,358,000 | +1123.4% | 631,700 | +1004.4% | 0.00% | – |
| Q3 2014 | $111,000 | -46.6% | 57,200 | 0.0% | 0.00% | – |
| Q2 2014 | $208,000 | +9.5% | 57,200 | 0.0% | 0.00% | – |
| Q1 2014 | $190,000 | +25.8% | 57,200 | 0.0% | 0.00% | – |
| Q4 2013 | $151,000 | -30.4% | 57,200 | -5.8% | 0.00% | – |
| Q3 2013 | $217,000 | +123.7% | 60,702 | +108.6% | 0.00% | – |
| Q2 2013 | $97,000 | – | 29,102 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |